1. Home
  2. UTHR vs PARAA Comparison

UTHR vs PARAA Comparison

Compare UTHR & PARAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • PARAA
  • Stock Information
  • Founded
  • UTHR 1996
  • PARAA 1986
  • Country
  • UTHR United States
  • PARAA United States
  • Employees
  • UTHR N/A
  • PARAA N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • PARAA Broadcasting
  • Sector
  • UTHR Health Care
  • PARAA Industrials
  • Exchange
  • UTHR Nasdaq
  • PARAA Nasdaq
  • Market Cap
  • UTHR 14.4B
  • PARAA 15.2B
  • IPO Year
  • UTHR 1999
  • PARAA N/A
  • Fundamental
  • Price
  • UTHR $291.72
  • PARAA $22.70
  • Analyst Decision
  • UTHR Buy
  • PARAA Sell
  • Analyst Count
  • UTHR 13
  • PARAA 15
  • Target Price
  • UTHR $393.08
  • PARAA $11.36
  • AVG Volume (30 Days)
  • UTHR 690.9K
  • PARAA 19.1K
  • Earning Date
  • UTHR 07-30-2025
  • PARAA 08-07-2025
  • Dividend Yield
  • UTHR N/A
  • PARAA 0.88%
  • EPS Growth
  • UTHR 18.86
  • PARAA N/A
  • EPS
  • UTHR 25.10
  • PARAA N/A
  • Revenue
  • UTHR $2,994,100,000.00
  • PARAA $28,720,000,000.00
  • Revenue This Year
  • UTHR $14.30
  • PARAA N/A
  • Revenue Next Year
  • UTHR $6.32
  • PARAA $0.75
  • P/E Ratio
  • UTHR $11.62
  • PARAA N/A
  • Revenue Growth
  • UTHR 19.84
  • PARAA N/A
  • 52 Week Low
  • UTHR $266.98
  • PARAA $16.59
  • 52 Week High
  • UTHR $417.82
  • PARAA $24.50
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 43.35
  • PARAA 54.29
  • Support Level
  • UTHR $281.97
  • PARAA $22.32
  • Resistance Level
  • UTHR $329.85
  • PARAA $22.80
  • Average True Range (ATR)
  • UTHR 9.11
  • PARAA 0.23
  • MACD
  • UTHR -3.44
  • PARAA 0.02
  • Stochastic Oscillator
  • UTHR 29.04
  • PARAA 79.17

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About PARAA Paramount Global

Paramount Global operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount's streaming platforms is created by the production studios housed within the firm's other two business segments.

Share on Social Networks: